Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria

Trial Profile

A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sevuparin (Primary) ; Atovaquone/proguanil
  • Indications Falciparum malaria
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Modus Therapeutics
  • Most Recent Events

    • 20 Dec 2017 According to a Modus Therapeutics media release, results from this trial have been published in PLOS ONE.
    • 20 Dec 2017 Results presented in a Modus Therapeutics media release.
    • 28 Nov 2014 According to Dilaforette media release, results were presented at the American Society of Tropical Medicine and Hygiene (ASTMH) meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top